
Press Release|Articles|December 17, 2024
Camber Pharmaceuticals Announces Addition of Erlotinib Tablets
Listen
0:00 / 0:00
Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Erlotinib Tablets.
Erlotinib Tablets are a kinase inhibitor indicated for:
- The treatment of patients with metastatic non-small cell lung cancer (NSCLC)
- First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Erlotinib Tablets are available in 25 mg, 100 mg, and 150 mg strengths, packaged in 30-count bottles.
To find out more information on Erlotinib Tablets please visit:
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
5




































































































